# EyePoint Inc. (EYPT)

Source: https://www.quantisnow.com/company/EYPT
Generated: 2026-11-15T05:59:26.845Z

- Ticker: EYPT
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Laboratory Analytical Instruments
- SEC CIK: 0001314102
- Website: eyepointpharma.com

## About

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor that is in Phase 1 clinical trials for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

## Latest EYPT news and filings

- 2026-11-12 21:05 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by EyePoint Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-eyepoint-inc-6787809)
- 2026-11-12 12:05 UTC [SEC Form 8-K] [EyePoint Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/eyepoint-inc-filed-sec-form-8-k-results-of-operations-and-6786114)
- 2026-11-12 12:00 UTC [Earnings] [EyePoint Reports Third Quarter 2026 Financial Results and Provides Recent Corporate Developments](https://www.quantisnow.com/insight/eyepoint-reports-third-quarter-2026-financial-results-and-provides-recent-6786017)
- 2026-11-06 12:00 UTC [EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings](https://www.quantisnow.com/insight/eyepoint-announces-participation-at-upcoming-investor-conferences-and-scientific-meetings-6777882)
- 2026-11-05 12:00 UTC [Earnings Date] [EyePoint to Report Third Quarter 2026 Financial Results on November 12, 2026](https://www.quantisnow.com/insight/eyepoint-to-report-third-quarter-2026-financial-results-on-november-6774416)
- 2026-11-04 12:51 UTC [SEC Schedule 13G] [Amendment: SEC Form SCHEDULE 13G/A filed by EyePoint Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-eyepoint-inc-6771401)
- 2026-10-27 21:51 UTC [SEC Form SCHEDULE 13G filed by EyePoint Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-eyepoint-inc-6760020)
- 2026-10-21 14:10 UTC [Market Insight] [EYPT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into EyePoint Pharmaceuticals (EYPT)](https://www.quantisnow.com/insight/eypt-investor-alert-levi-korsinsky-notifies-investors-of-investigation-into-6753225)
- 2026-10-20 11:47 UTC [Analyst Downgrade] [EyePoint downgraded by Analyst](https://www.quantisnow.com/insight/eyepoint-downgraded-by-analyst-6751450)
- 2026-10-20 11:28 UTC [Analyst Downgrade] [EyePoint downgraded by Mizuho with a new price target](https://www.quantisnow.com/insight/eyepoint-downgraded-by-mizuho-with-a-new-price-target-6751404)
- 2026-10-19 17:08 UTC [Analyst Downgrade] [EyePoint downgraded by Guggenheim](https://www.quantisnow.com/insight/eyepoint-downgraded-by-guggenheim-6750383)
- 2026-10-19 11:15 UTC [EyePoint Announces Strategic Prioritization](https://www.quantisnow.com/insight/eyepoint-announces-strategic-prioritization-6750065)
- 2026-10-19 11:00 UTC [Earnings Date] [EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU™ in Wet AMD](https://www.quantisnow.com/insight/eyepoint-announces-topline-results-from-lucia-the-second-pivotal-phase-6750041)
- 2026-10-19 14:45 UTC [Analyst Downgrade] [EyePoint downgraded by Jefferies with a new price target](https://www.quantisnow.com/insight/eyepoint-downgraded-by-jefferies-with-a-new-price-target-6750021)
- 2026-10-19 13:22 UTC [SEC Form 8-K] [SEC Form 8-K filed by EyePoint Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-eyepoint-inc-6749991)
- 2026-10-19 11:05 UTC [SEC Form 8-K] [SEC Form 8-K filed by EyePoint Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-eyepoint-inc-6749852)
- 2026-10-07 11:22 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by EyePoint Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-eyepoint-inc-6739689)
- 2026-09-16 11:00 UTC [EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/eyepoint-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6716857)
- 2026-09-10 11:05 UTC [SEC Form 8-K] [EyePoint Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/eyepoint-inc-filed-sec-form-8-k-other-events-financial-statements-6710800)
- 2026-09-08 15:50 UTC [SEC Form SCHEDULE 13G filed by EyePoint Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-eyepoint-inc-6708018)
- 2026-09-02 12:18 UTC [Analyst Downgrade] [EyePoint downgraded by TD Cowen with a new price target](https://www.quantisnow.com/insight/eyepoint-downgraded-by-td-cowen-with-a-new-price-target-6702438)
- 2026-09-02 11:00 UTC [EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting](https://www.quantisnow.com/insight/eyepoint-announces-participation-at-upcoming-investor-conferences-and-scientific-meeting-6702229)
- 2026-08-24 20:10 UTC [SEC Form 4] [Chief Financial Officer Elston George acquired 5,000 shares, gifted 64,953 shares, received a gift of 64,953 shares and disposed of 5,000 shares, decreasing direct ownership by 65% to 32,517 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-elston-george-acquired-5000-shares-gifted-64953-6692714)
- 2026-08-18 20:08 UTC [Insider Buy] [Director Zaderej Karen L. bought $52,258 worth of shares (10,600 units at $4.93), increasing direct ownership by 28% to 49,100 units (SEC Form 4)](https://www.quantisnow.com/insight/director-zaderej-karen-l-bought-52258-worth-of-shares-10600-6686550)
- 2026-08-18 12:13 UTC [Analyst Downgrade] [EyePoint downgraded by Chardan Capital Markets with a new price target](https://www.quantisnow.com/insight/eyepoint-downgraded-by-chardan-capital-markets-with-a-new-price-6685956)
- 2026-08-18 12:06 UTC [Analyst Downgrade] [EyePoint downgraded by RBC Capital Mkts with a new price target](https://www.quantisnow.com/insight/eyepoint-downgraded-by-rbc-capital-mkts-with-a-new-price-6685943)
- 2026-08-18 12:06 UTC [Analyst Downgrade] [EyePoint downgraded by H.C. Wainwright](https://www.quantisnow.com/insight/eyepoint-downgraded-by-hc-wainwright-6685940)
- 2026-08-17 13:32 UTC [Analyst Downgrade] [EyePoint downgraded by Cantor Fitzgerald](https://www.quantisnow.com/insight/eyepoint-downgraded-by-cantor-fitzgerald-6684611)
- 2026-08-17 12:50 UTC [SEC Form 8-K] [EyePoint Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/eyepoint-inc-filed-sec-form-8-k-other-events-financial-statements-6684495)
- 2026-08-17 11:00 UTC [Earnings Date] [EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD](https://www.quantisnow.com/insight/eyepoint-announces-topline-data-from-lugano-the-first-of-two-6684159)
- 2026-08-14 20:32 UTC [EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/eyepoint-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6683176)
- 2026-08-05 20:18 UTC [SEC Form S-8] [SEC Form S-8 filed by EyePoint Inc.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-eyepoint-inc-6665590)
- 2026-08-05 20:05 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by EyePoint Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-eyepoint-inc-6665094)
- 2026-08-05 11:05 UTC [SEC Form 8-K] [EyePoint Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/eyepoint-inc-filed-sec-form-8-k-results-of-operations-and-6663902)
- 2026-08-05 11:00 UTC [Earnings Date] [EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments](https://www.quantisnow.com/insight/eyepoint-reports-second-quarter-2026-financial-results-and-highlights-recent-6663817)
- 2026-07-30 11:05 UTC [SEC Form 8-K] [EyePoint Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/eyepoint-inc-filed-sec-form-8-k-other-events-financial-statements-6654929)
- 2026-07-30 11:00 UTC [EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)](https://www.quantisnow.com/insight/eyepoint-completes-enrollment-of-both-pivotal-phase-3-trials-of-6654822)
- 2026-07-17 20:05 UTC [SEC Form 8-K] [EyePoint Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits](https://www.quantisnow.com/insight/eyepoint-inc-filed-sec-form-8-k-entry-into-a-material-6640980)
- 2026-07-16 12:54 UTC [Analyst Coverage Initiated] [Stifel initiated coverage on EyePoint with a new price target](https://www.quantisnow.com/insight/stifel-initiated-coverage-on-eyepoint-with-a-new-price-target-6639218)
- 2026-07-16 11:00 UTC [EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/eyepoint-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-6638943)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/EYPT
- Earnings history: https://www.quantisnow.com/earnings/EYPT
- Dividend history: https://www.quantisnow.com/dividends/EYPT
- Insider transactions: https://www.quantisnow.com/insiders/EYPT
- Options chain: https://www.quantisnow.com/options/EYPT
- SEC 8-K filings only: https://www.quantisnow.com/company/EYPT/8-k
- RSS and alerts for EYPT: https://www.quantisnow.com/docs/rss-feeds.md